SubsidieMeestersAutomated retinal scans for early detection of diabetic eye diseases through use of artificial intelligence
Oivi aims to enhance accessibility to affordable eye care by developing a low-cost, automated retinal imaging device for early detection of diabetic retinopathy, preventing blindness in millions.
Projectdetails
Introduction
Oivi provides affordable eye care for all and prevents unnecessary blindness by providing a low-cost camera for retinal (fundus) photography, with fully automated image capture and diagnostics.
Problem Statement
Oivi is a point-of-care device for eye screening of diabetic retinopathy (DR). DR affects over 160 million people worldwide and is the most common cause of blindness among working-age adults.
Importance of Early Detection
Yet, early detection can successfully prevent vision loss in 95% of the cases. Current solutions for DR screening are expensive and require extensive training that limits accessibility to patients, especially in developing countries.
Unique Solution
Oivi is a unique combination of:
- Automated
- Easy-to-use
- Low-cost
- Integrated Machine Learning/Artificial Intelligence solutions (for image capturing and DR diagnostics)
- Highly portable design
Project Goals
Within the iScan project, we want to:
- Mature the device and its diagnostic functionalities
- Clinically validate our solution
- Assure regulatory approvals
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.622.500 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- OIVI ASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Optical imaging platform for high-throughput longitudinal studies of the eye in disease modelsThe OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use. | ERC POC | € 150.000 | 2023 | Details |
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared careI(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care. | EIC Pathfinder | € 3.454.613 | 2024 | Details |
Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast EvaluationVISIONSAFE aims to enhance early detection of preventable eye diseases by extracting and analyzing macro- and microstructural biomarkers from clinical eye images using advanced data science techniques. | ERC STG | € 1.497.873 | 2025 | Details |
Haalbaarheid van bevolkingsonderzoek met behulp van kunstmatige intelligentieHet project ontwikkelt een AI-gebaseerde dienst voor vroegtijdige glaucoomdetectie om kosten te verlagen en de impact van blindheid te beperken door bevolkingsonderzoek te verbeteren. | MIT Haalbaarheid | € 19.472 | 2023 | Details |
Optical imaging platform for high-throughput longitudinal studies of the eye in disease models
The OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use.
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care.
Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast Evaluation
VISIONSAFE aims to enhance early detection of preventable eye diseases by extracting and analyzing macro- and microstructural biomarkers from clinical eye images using advanced data science techniques.
Haalbaarheid van bevolkingsonderzoek met behulp van kunstmatige intelligentie
Het project ontwikkelt een AI-gebaseerde dienst voor vroegtijdige glaucoomdetectie om kosten te verlagen en de impact van blindheid te beperken door bevolkingsonderzoek te verbeteren.